Anne-Marie C Dingemans (A-M C Dingemans)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 17

Top Topics

Combination Therapy

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

CPT: pharmacometrics & systems pharmacology

JCO precision oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology (2024)
Jordi Remon, Benjamin Besse, Santiago Ponce Aix, Ana Callejo, Kamal Al-Rabi, Reyes Bernabe, Laurent Greillier, Margarita Majem, Noemí Reguart, Isabelle Monnet, Sophie Cousin, Pilar Garrido Lopez, Gilles Robinet, Rosario Garcia Campelo, Anne Madroszyk, Julien Mazieres, Hubert Curcio, Bartosz Wasag, Yassin Pretzenbacher, Fanny Grillet, Anne-Marie C Dingemans, Rafal Dziadziuszko
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR -Mutant Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (12) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Jordi Remon, Benjamin Besse, Santiago Ponce Aix, Ana Callejo, Kamal Al-Rabi, Reyes Bernabe, Laurent Greillier, Margarita Majem, Noemí Reguart, Isabelle Monnet, Sophie Cousin, Pilar Garrido Lopez, Gilles Robinet, Rosario Garcia Campelo, Anne Madroszyk, Julien Mazieres, Hubert Curcio, Bartosz Wasag, Yassin Pretzenbacher, Fanny Grillet, Anne-Marie C Dingemans, Rafal Dziadziuszko
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR -Mutant Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Jordi Remon, Benjamin Besse, Santiago Ponce Aix, Ana Callejo, Kamal Al-Rabi, Reyes Bernabe, Laurent Greillier, Margarita Majem, Noemí Reguart, Isabelle Monnet, Sophie Cousin, Pilar Garrido Lopez, Gilles Robinet, Rosario Garcia Campelo, Anne Madroszyk, Julien Mazieres, Hubert Curcio, Bartosz Wasag, Yassin Pretzenbacher, Fanny Grillet, Anne-Marie C Dingemans, Rafal Dziadziuszko
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR -Mutant Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (12) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Jordi Remon, Benjamin Besse, Santiago Ponce Aix, Ana Callejo, Kamal Al-Rabi, Reyes Bernabe, Laurent Greillier, Margarita Majem, Noemí Reguart, Isabelle Monnet, Sophie Cousin, Pilar Garrido Lopez, Gilles Robinet, Rosario Garcia Campelo, Anne Madroszyk, Julien Mazieres, Hubert Curcio, Bartosz Wasag, Yassin Pretzenbacher, Fanny Grillet, Anne-Marie C Dingemans, Rafal Dziadziuszko
Overall Survival From the EORTC LCG-163 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR -Mutant Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Sophie M Ernst, Sevim Uzun, Marthe S Paats, Ronald van Marion, Peggy N Atmodimedjo, Evert de Jonge, Ron H N van Schaik, Joachim G J V Aerts, Jan H von der Thüsen, Hendrikus Jan Dubbink, Anne-Marie C Dingemans
Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases. JCO precision oncology 7 (2023)
Sophie M Ernst, Sevim Uzun, Marthe S Paats, Ronald van Marion, Peggy N Atmodimedjo, Evert de Jonge, Ron H N van Schaik, Joachim G J V Aerts, Jan H von der Thüsen, Hendrikus Jan Dubbink, Anne-Marie C Dingemans
Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases. JCO precision oncology 7 (2023)
Sophie M Ernst, Sevim Uzun, Marthe S Paats, Ronald van Marion, Peggy N Atmodimedjo, Evert de Jonge, Ron H N van Schaik, Joachim G J V Aerts, Jan H von der Thüsen, Hendrikus Jan Dubbink, Anne-Marie C Dingemans
Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases. JCO precision oncology 7 (2023)
Sophie M Ernst, Sevim Uzun, Marthe S Paats, Ronald van Marion, Peggy N Atmodimedjo, Evert de Jonge, Ron H N van Schaik, Joachim G J V Aerts, Jan H von der Thüsen, Hendrikus Jan Dubbink, Anne-Marie C Dingemans
Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases. JCO precision oncology 7 (2023)
Melinda A Pruis, M S Paats, W R R Geurts, Hendrikus Jan Dubbink, Anne-Marie C Dingemans
Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation. JCO precision oncology 5 (2022)
Melinda A Pruis, Floris H Groenendijk, K Sangeeta Badloe, Andrea van Puffelen, Debbie G J Robbrecht, Winand N M Dinjens, Stefan Sleijfer, Anne-Marie C Dingemans, Jan H von der Thusen, Paul Roepman, Martijn Paul Lolkema
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. British journal of cancer 127 (4) (2022)
Jules L Derks, Ernst-Jan M Speel, Anne-Marie C Dingemans
Adjuvant Chemotherapy in Patients With Stage I-IIIA Large-Cell Neuroendocrine Carcinoma: Should a Different Approach Be Applied Than for Small-Cell Lung Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (13) (2021)